Hikma Pharmaceuticals’ (HIK) “Underweight” Rating Reaffirmed at Barclays
Hikma Pharmaceuticals (LON:HIK)‘s stock had its “underweight” rating reissued by equities research analysts at Barclays in a note issued to investors on Monday.
A number of other analysts have also recently commented on HIK. Peel Hunt reaffirmed a “hold” rating on shares of Hikma Pharmaceuticals in a research note on Thursday, May 31st. Citigroup reaffirmed a “buy” rating and issued a GBX 1,675 ($21.82) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, July 3rd. Numis Securities cut Hikma Pharmaceuticals to a “hold” rating and set a GBX 1,560 ($20.32) price target for the company. in a research note on Thursday, August 9th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 1,050 ($13.68) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, August 21st. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 1,330.22 ($17.33).
Shares of HIK stock opened at GBX 1,953 ($25.44) on Monday. Hikma Pharmaceuticals has a one year low of GBX 814.20 ($10.61) and a one year high of GBX 2,346 ($30.56).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Read More: Should I invest in “strong buy” stocks?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.